Description
Class A61P : THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
Subclass 1/18: Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
A61P 1/18
Sub-Class
Stats
- 103 US PATENTS IN FORCE
- 32 US APPLICATIONS PENDING
- 30 Total Patent Owners
- 1,620 TOTAL INVENTORS
Recent Patents
| Patent # | Title | Filing Date | Issue Date | Patent Owner |
|---|---|---|---|---|
| 12214083 | Pharmaceutical composition and administrations thereof | Jul 20, 23 | Feb 04, 25 | Vertex Pharmaceuticals Incorporated |
| 12194015 | Composition comprising ferrous amino acid particles and method for treating or ameliorating pancreas-related disease using the same | Dec 20, 18 | Jan 14, 25 | Profeat Biotechnology Co., Ltd. |
| 12178848 | Methods and compositions for the treatment of exocrine pancreatic insufficiency | Mar 11, 22 | Dec 31, 24 | 501 Board of Regents The University of Texas System |
| 12128131 | Treatment of epithelial cysts by intracystic injection of antineoplastic particles | Jul 13, 23 | Oct 29, 24 | CritiTech Inc. |
| 12109190 | Urolithins as immune response enhancers | Aug 24, 22 | Oct 08, 24 | AMAZENTIS SA |
| 12084485 | Long acting glucagon like polypeptide-1 (GLP-1) receptor agonists and methods of use | Dec 16, 21 | Sep 10, 24 | i2o Therapeutics, Inc. |
| 12076368 | Treatment of liver, biliary tract and pancreatic disorders | Apr 28, 17 | Sep 03, 24 | Novozymes A/S |
| 12071642 | Engineered amylase variants | Sep 06, 23 | Aug 27, 24 | Codexis Inc.; Société des Produits Nestlé S.A.; |
| 12065496 | Antibody molecules and conjugates | Nov 09, 22 | Aug 20, 24 | AstraZeneca AB |
| 12060367 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | May 09, 23 | Aug 13, 24 | Boehringer Ingelheim International GmbH; Board of Governors of Wayne State University and Vanderbilt University; |
| 12053454 | Compositions for cryopreservation and methods of use thereof | Dec 31, 18 | Aug 06, 24 | EVERGREEN BIOSCIENCES |
| 12023306 | Compositions comprising a cannabinoid and spilanthol | Mar 01, 21 | Jul 02, 24 | SCICANN THERAPEUTICS INC. |
| 11957699 | Composition comprising punicalagin for inhibiting PAR2 activity | Jul 30, 19 | Apr 16, 24 | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 11959108 | Engineered protease variants | Aug 27, 21 | Apr 16, 24 | Codexis Inc.; Societe des Produits Nestle SA; |
| 11938172 | Method for regulating and controlling GLP-1/GLP-1R and drug | Jun 19, 18 | Mar 26, 24 | TALENGEN INTERNATIONAL LIMITED |
| 11918553 | Anti-oncogenic phytochemicals comprising substituted henicosanoic acid and henicosenoic acid | Jun 16, 23 | Mar 05, 24 | Ostentus Therapeutics, Inc. |
| 11834499 | Claudin18 antibodies and methods of treating cancer | Oct 03, 22 | Dec 05, 23 | The Regents of the University of California |
| 11771735 | Composition for improving or preventing nonalcoholic fatty liver | Nov 19, 21 | Oct 03, 23 | KOHJIN LIFE SCIENCES CO., LTD.; PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY; KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION; President of Saga University; |
| 11767519 | Engineered amylase variants | Aug 27, 21 | Sep 26, 23 | Codexis Inc.; Societe des Produits Nestle SA; |
| 11758928 | Compositions and methods that modulate phosphorus or enzymes in a companion animal | Dec 12, 17 | Sep 19, 23 | Société des Produits Nestlé S.A. |
Recent Publications
| Publication # | Title | Filing Date | Pub Date | Patent Owner |
|---|---|---|---|---|
| 2025/0115,548 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Oct 14, 24 | Apr 10, 25 | Not available |
| 2025/0051,765 | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Apr 29, 24 | Feb 13, 25 | Not available |
| 2025/0002,504 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Jun 26, 24 | Jan 02, 25 | Not available |
| 2024/0384,251 | ENGINEERED AMYLASE VARIANTS | Jul 30, 24 | Nov 21, 24 | Not available |
| 2024/0360,226 | ANTIBODY MOLECULES AND CONJUGATES | Jun 25, 24 | Oct 31, 24 | Not available |
| 2024/0335,468 | TREATMENT OF RESPIRATORY CONDITIONS | Jul 08, 22 | Oct 10, 24 | Not available |
| 2024/0307,384 | PYRAZINE-CONTAINING COMPOUND | Mar 01, 24 | Sep 19, 24 | Not available |
| 2024/0269,165 | FINE SILICON PARTICLE-CONTAINING PREVENTIVE OR THERAPEUTIC AGENT FOR DISEASES | May 31, 22 | Aug 15, 24 | Osaka University |
| 2024/0261,366 | TREATMENT OF BETA-CELL FAILURE OR DYSFUNCTION | Jan 30, 24 | Aug 08, 24 | NOVMETAPHARMA CO., LTD.; Korea Advanced Institute of Science and Technology; |
| 2024/0261,447 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO THE HEPATOPANCREATIC ANATOMICAL REGION | Jul 25, 22 | Aug 08, 24 | Not available |
| 2024/0226,089 | RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (RAAS) INHIBITORS IN THE TREATMENT OF PANCREATIC DUCTAL CARCINOMA | Jan 10, 23 | Jul 11, 24 | Not available |
| 2024/0228,585 | FC-FUSION PROTEIN THERAPEUTIC FOR THE TREATMENT OF PANCREATITIS | May 02, 22 | Jul 11, 24 | Harvard University President and Fellows of Harvard College |
| 2024/0182,406 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Mar 14, 22 | Jun 06, 24 | Not available |
| 2024/0150,423 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | Nov 09, 20 | May 09, 24 | Nanjing Finepeptide Biopharmaceutical Co.,Ltd |
| 2024/0139,337 | METHOD FOR TREATING A CANCER AND/OR CANCER METASTASIS | Nov 02, 22 | May 02, 24 | Not available |
| 2024/0041,980 | COMPOSITIONS AND METHODS FOR TREATING TYPE 2 DIABETES USING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) | Aug 25, 23 | Feb 08, 24 | Not available |
| 2024/0026,326 | ENGINEERED AMYLASE VARIANTS | Sep 06, 23 | Jan 25, 24 | Not available |
| 2024/0009,163 | Anti-Oncogenic Phytochemicals and Methods and Uses for Treating Cancer | Jun 16, 23 | Jan 11, 24 | Ostentus Therapeutics, Inc. |
| 2023/0270,855 | Genetically Modified T-Cells and PI3K/AKT Inhibitors For Cancer Treatment | Apr 09, 19 | Aug 31, 23 | Not available |
| 2023/0241,000 | GSK3 INHIBITOR-LOADED NANO FORMULATIONS AS A CANCER IMMUNOTHERAPEUTIC | Jun 29, 21 | Aug 03, 23 | The Regents of the University of California |
Top Owners in This Subclass
| Upgrade to the Professional Level to view Top Owners for this Subclass.Learn More |
|---|
Patents Issued To Date - By Filing Year
Average Time to Issuance
- 28 Months (last 2 years Issuances)
- 28 Months (last 5 years Issuances)